Screening of inFlammation to enable personalized Medicine
This transdisciplinary project will combine fundamental immunological research with novel nanomaterial-based biosensor development translated into proof-of-principle diagnostics to revolutionize doctors’ ability to diagnose and tr...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BIO2014-53091-C3-1-R
DISEÑO DE NANOVACUNAS TERAPEUTICAS BASADAS EN PEPTIDOS: APLI...
157K€
Cerrado
PredicTOOL
Nanomethods to understand what makes an endogenous protein i...
1M€
Cerrado
PGC2018-099870-A-I00
PLATAFORMA SENSORA NANOPLASMONICA PARA EL ANALISIS BIOMIMETI...
56K€
Cerrado
PID2020-119087RB-I00
TEST RAPIDOS BASADOS EN NANOMATERIALES PARA DETERMINACION DE...
198K€
Cerrado
PRE2021-099887
NANOESTRUCTURAS BIOMIMETICAS DERIVADAS DE CELULAS DENDRITICA...
101K€
Cerrado
DPI2015-68917-R
DESARROLLO DE SENSORES NANOMECANICOS CON RESPUESTA CROMATICA...
131K€
Cerrado
Información proyecto SciFiMed
Duración del proyecto: 55 meses
Fecha Inicio: 2020-05-26
Fecha Fin: 2024-12-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
This transdisciplinary project will combine fundamental immunological research with novel nanomaterial-based biosensor development translated into proof-of-principle diagnostics to revolutionize doctors’ ability to diagnose and treat severe diseases plaguing millions of Europeans.
Impaired defence against infections, incurable renal, eye and autoimmune diseases represent a huge burden on human health and consequently cost our society not only personal suffering but also hundreds of billions of Euros p.a.. All of these diseases share an association with a dysregulation of the complement system, a major effector of the innate immune system. There still is a huge discrepancy between what we know and what we need to know about the complement system’s role in these diseases in order to prevent, diagnose and treat them appropriately, effectively, and efficiently .
Complement factor H (FH) and FH-related (FHR) proteins are strongly associated with these systemic and organ-specific pathologies. In contrast to FH, the function of the remaining six highly homologous FHR proteins is mostly unknown and, hence, their role in the different disease-specific pathogenic mechanisms remain elusive.
Our EU consortium (8 partners from 4 countries) will unravel the mysteries of the FH-protein family’s contributions to diseases. Then, via an ambitious and transdisciplinary fundamental science-to-technology transfer, a proof-of-principle for a multiplex detection system will be developed to simultaneously quantify and analyse the functional activity of all seven FH-protein family members in patient samples – on site, putting diagnostic technology directly into physicians’ hands.
In the future, this high-impact project propels immunological research in Europe, enables new product development of bioanalytical companies, modernizes the EU-diagnostic market and provides new perspectives for patient treatment, which in turn will pave the way for novel approaches for drug development.